Journal club: Bullous pemphigoid

Department of Dermatology, Hospital Universitario Puerta de Hierro, ajadahonda, Spain CIRI, Centre International de Recherche en Infectiologie, (Team pidermal Immunity and Allergy); INSERM, U1111; Univ Lyon; niversité de Lyon 1; Ecole Normale Supérieure de Lyon; CNRS, UMR 308, Lyon, France; Department of Dermatology and Allergology, Centre ospitalier Universitaire de Saint-Etienne, Saint-Priest-en-Jarez, France Department of Dermatology, Venereology and Allergology, University ospital Würzburg, Würzburg, Germany Dermatology of Department, Cambridge University Hospitals, ddenbrookes Hospital, Cambridge, UK Department of Dermatology, Centro Hospitalar Universitário do Porto, orto, Portugal Department of Dermatology, Hospital General Universitario Gregorio arañón, Madrid, Spain roselld@gmail.com

[1]  M. Richard,et al.  International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg−1 per day starting dose of oral corticosteroids to treat bullous pemphigoid , 2021, The British journal of dermatology.

[2]  D. Zillikens,et al.  The impact of lesional inflammatory cellular infiltrate on the phenotype of bullous pemphigoid , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  L. Borradori,et al.  Mixed Individual-Aggregate Data on All-Cause Mortality in Bullous Pemphigoid: A Meta-analysis. , 2021, JAMA dermatology.

[4]  C. Moltrasio,et al.  International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut‐off values for defining mild, moderate and severe types of bullous pemphigoid * , 2020, The British journal of dermatology.

[5]  V. A. Jones,et al.  A Review Comparing International Guidelines for the Management of Bullous Pemphigoid, Pemphigoid Gestationis, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita , 2020, American Journal of Clinical Dermatology.

[6]  E. Berti,et al.  New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update , 2019, Frontiers in Immunology.

[7]  W. Boehncke,et al.  Autoreactive T-Lymphocytes in Inflammatory Skin Diseases , 2019, Front. Immunol..

[8]  K. Kridin,et al.  The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations , 2018, Front. Med..

[9]  R. Bergman,et al.  Ethnic variations in the epidemiology of bullous pemphigoid in Israel , 2018, International journal of dermatology.

[10]  A. Reich,et al.  The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment. , 2017, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[11]  A. Reich,et al.  Assessment of Intra- and Inter-Rater Reliability of Three Methods for Measuring Atopic Dermatitis Severity: EASI, Objective SCORAD, and IGA , 2017, Dermatology.

[12]  Enno Schmidt,et al.  Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial , 2017, The Lancet.

[13]  D. Murrell,et al.  The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use? , 2017, Acta dermato-venereologica.

[14]  T. Ruzicka,et al.  Bullous pemphigoid. , 2017, Autoimmunity reviews.

[15]  H. Shimizu,et al.  Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid. , 2016, The Journal of investigative dermatology.

[16]  C. Alderman.  Saving the Elderly From Drug-Related Harm , 2016, The Annals of pharmacotherapy.

[17]  D. Zillikens,et al.  Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology , 2015, The British journal of dermatology.

[18]  F. Antonicelli,et al.  Assessment of Bullous Pemphigoid Disease Area Index during Treatment: A Prospective Study of 30 Patients , 2014, Dermatology.

[19]  D. Zillikens,et al.  Pemphigoid diseases , 2013, The Lancet.

[20]  D. Sotiriadis,et al.  Association of Autoantibodies to BP180 with Disease Activity in Greek Patients with Bullous Pemphigoid , 2012, Clinical & developmental immunology.

[21]  H. Shimizu,et al.  Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. , 2012, Journal of the American Academy of Dermatology.

[22]  J. Roujeau,et al.  Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. , 2011, The Journal of investigative dermatology.

[23]  P. Middleton,et al.  Interventions for bullous pemphigoid. , 2010, The Cochrane database of systematic reviews.

[24]  J. Berlin,et al.  The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. , 2005, The Journal of investigative dermatology.

[25]  L. Vaillant,et al.  A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. , 2002, The New England journal of medicine.

[26]  G. Lorette,et al.  PLASMA EXCHANGE IN BULLOUS PEMPHIGOID , 1984, The Lancet.